Greg Inguaggiato is a Senior Analyst at Catalio Capital Management, LP focusing on public equity investments across Commercial Biotech / Pharma and Mid- / Late-stage Biotech.
Prior to joining Catalio, Greg was a Senior Analyst at HealthCor Management, a global healthcare-focused long short equity fund, where he worked from 2017 to 2022. Greg was responsible for recommending and managing public equity positions across SMID / Large-cap Biotech and Pharma. Earlier in his career, he was an Investment Banking Analyst covering Global Healthcare at Morgan Stanley.
Greg earned his B.S. degree in Finance and Accounting from the NYU Stern School of Business.